public access

Alzheimer’s disease

Alzheimer’s disease is a neurodegenerative disease that seems to start well before symptoms first appear. There is currently no treatment, but there are options with potential.

According to the WHO1, Alzheimer’s disease affects more than 35 million people around the world. This number is expected to almost double every 20 years, reaching 115.4 million in 20502.

Memory loss: the first visible symptom of the disease

In addition to the characteristic memory loss, Alzheimer’s disease can also cause speech and comprehension difficulties, attention and concentration problems, loss of dexterity (apraxia), and, in some cases, problems recognizing objects or faces (agnosia). Cognitive symptoms get worse over time and behavioral symptoms start to appear, such as anxiety, apathy, irritability, sleeping disorders, disinhibition, and agitation2

From a scientific perspective

Two kinds of lesions are characteristic of Alzheimer’s disease: the abnormal accumulation of beta-amyloid peptide plaque deposits and neurofibrillary degeneration. Although the causes of these phenomena remain unknown, the involvement of intestinal microbiota is being studied. Certain intestinal bacteria seem to produce amyloid peptides similar to those observed in the brains of these patients, which accelerate cerebral inflammation3 involved in the disease.

Risk factors identified

Several genetic and environmental risk factors have been identified2: high blood pressure, high cholesterol, tobacco use, sedentary lifestyle, unbalanced diet, and lack of cognitive stimulation.

Promising prospects for therapy

A diagnosis of Alzheimer’s disease, established during a specialized memory consultation, relies on various exams: neuropsychological exam, MRI, lumbar puncture2, etc. 
Although there is currently no treatment, immunotherapy4 appears to be a promising option. Changing the microbiota by affecting diet and adding probiotics and prebiotics may prevent or reduce the risk of cognitive decline3,5

1. La démence. OMS. Avril 2016. 
2. L'association pour la recherche sur Alzheimer 
3. Pistollato F et al. M. Role of gut microbiota and nutrients in amyloid formation and pathogenesis of Alzheimer disease. Nutr Rev. 2016 Oct;74(10):624-34. doi: 10.1093/nutrit/nuw023
4. L'immunothérapie pour soigner la maladie d'Alzheimer. Inserm, décembre 2016 et Interleukin-2 improves amyloid pathology, synaptic failure and memory in Alzheimer’s disease mice, Brain, 20 décembre 2016 
5. Microbiote intestinal et santé. Inserm.



  • Parkinson's disease

    For roughly 15 years, it has been hypothesized that Parkinson’s disease does not originate exclusively in the brain, ...

  • Schizophrenia

    Recent hypotheses suggest that an alteration in the microbiota that sustains inflammation could favor schizophrenia. ...

  • Multiple sclerosis

    The intestinal microbiota may become a target for therapy in the fight against multiple sclerosis (MS). The results o...

  • Anxiety disorders

    The discovery of a role of the intestinal microbiota in anxiety disorders that affect hundreds of millions of individ...

  • Mood disorders

    Mood disorders, depression and bipolar disorder affect people of all ages and sometimes cause severe mental distress....

  • Autism-Spectrum disorders

    Previously called pediatric schizophrenia, autism-spectrum disorders (ASDs) now include autistic disorders and other ...

Biocodex Microbiota Institute overview

The Biocodex Microbiota Institute: an international leader in microbiota